374 related articles for article (PubMed ID: 17786355)
1. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
[TBL] [Abstract][Full Text] [Related]
2. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
[TBL] [Abstract][Full Text] [Related]
3. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
4. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
6. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
7. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
8. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.
Dinets A; Hulchiy M; Sofiadis A; Ghaderi M; Höög A; Larsson C; Zedenius J
Eur J Endocrinol; 2012 Jun; 166(6):1049-60. PubMed ID: 22457234
[TBL] [Abstract][Full Text] [Related]
9. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
10. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
11. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
[TBL] [Abstract][Full Text] [Related]
13. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
14. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
15. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
[TBL] [Abstract][Full Text] [Related]
16. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
[TBL] [Abstract][Full Text] [Related]
17. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
18. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas.
Puxeddu E; Moretti S; Giannico A; Martinelli M; Marino C; Avenia N; Cristofani R; Farabi R; Reboldi G; Ribacchi R; Pontecorvi A; Santeusanio F
Eur J Endocrinol; 2003 May; 148(5):505-13. PubMed ID: 12720532
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
20. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
Zhu XL; Zhou XY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
